Preparation of 188Re-HEDP as a bone tumor radionuclide therapeutic

Journal
Macedonian Pharmaceutical Bulletin
Date Issued
2022-12-31
Author(s)
DOI
10.33320/maced.pharm.bull.2022.68.03.133
Abstract
Re-HEDP (hydroxyethylidenediphosphonate) is an osteotropic radiopharmaceutical used in palliative treatment of primary and metastatic bone tumors, in addition to external beam therapy (Liepe, 2018). According to its chemical structure, it is a complex compound composed of a bisphosphonate ligand molecule that incorporates an atom of the radioactive 188Re, which is a beta-emitting radionuclide whose physical characteristics are suitable for its therapeutic use. The energy of its gamma radiation is very similar to the gamma radiation of technetium-99m, which allows monitoring its biodistribution with conventional gamma cameras. Another important feature of 188Re is that it is a generator product obtained from 188W/188Re generator without the presence of a "carrier" which facilitates its widespread use (Lee et al., 2009). The main aim was to present the preparation and quality control of 188Re-HEDP for clinical application in therapeutic nuclear medicine.